Regulus Therapeutics (NASDAQ:RGLS) Earns Buy Rating from Canaccord Genuity Group
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity Group in a research note issued on Monday,Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares […]
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity Group in a research note issued on Monday,Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares […]
